Investors & Media

Investors & Media

Welcome to our investor page

Harnessing the immune system’s full potential to fight human disease.

Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. We exploit a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Our broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on our deep expertise in mRNA vaccine development and in-house manufacturing capabilities, we and our collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside a diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.


Press Releases

9 April 2021

Pfizer and BioNTech Request Regulatory Agencies Expand Emergency Use of Their C..

1 April 2021

Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Throug..

31 March 2021

Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine S..

Press releases (more)

Upcoming Events

April 28, 2021

Kempen & Co. Life Sciences Conference

May 10, 2021 at 8:00 AM EDT

First Quarter 2021 Earnings Call

May 11, 2021 at 9:30 AM EDT

BofA Securities Virtual 2021 Healthcare Conference

Upcoming events (more)

Stock Quote

Apr 16, 2021 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.